Five Prime Therapeutics, Inc. (FPRX) saw its loss widen to $33.44 million, or $1.21 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $13.04 million, or $0.49 a share.
Revenue during the quarter surged 55.44 percent to $10.14 million from $6.52 million in the previous year period.
Operating loss for the quarter was $34.11 million, compared with an operating loss of $20.39 million in the previous year period.
"We had a productive quarter at Five Prime, in which we made notable progress in our clinical and preclinical programs," said Lewis T. "Rusty" Williams, M.D., Ph.D., president and chief executive officer of Five Prime. "We achieved an important milestone by completing enrollment in the Phase 2 part of the ongoing trial of cabiralizumab in patients with pigmented villonodular synovitis, or PVNS. Additionally, we have completed enrollment in some of the Phase 1b cohorts in the cabiralizumab immuno-oncology trial."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]